LOGIN  |  REGISTER
Amneal Pharmaceuticals
Astria Therapeutics

Cue Health to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

May 31, 2023 | Last Trade: US$0.04 0.00 0.00

SAN DIEGO, Calif. / May 31, 2023 / Business Wire / Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 4:00 p.m. Pacific Time at the Waldorf Astoria Monarch Beach Resort & Club.

A live audio webcast and replay of the presentation may be accessed for 180 days on the “Investor Relations” section of the company’s website at: https://cuehealth.com/.

About Cue Health
Cue Health Inc. (Nasdaq: HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. The Cue Health platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point of care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue’s customers include federal and state public sector agencies and the private sector, which includes healthcare providers, enterprises, and individual consumers. Cue’s COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription. Cue has since received Emergency Use Authorization from the FDA for its molecular mpox test at the point of care and, to expand its test menu, the company has a number of other submissions under review by the FDA. Cue, founded in 2010, owns over 100 patents and is headquartered in San Diego. For more information, please visit www.cuehealth.com.

Viking Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB